Jody A. Charnow

New findings could have implications for the use of salvage therapies.

Investigators analyzed data from 3 randomized controlled trials and data from their own prospective institutional database.

Investigators performed a subgroup analysis of the phase 3 ARASENS trial.

Grade 2 or higher gastrointestinal toxicities after hypofractionated prostate cancer radiation therapy occurred in a significantly lower proportion of men who received a hyaluronic acid spacer compared with those who did not.

Investigators estimated prevalence based on the number of de novo and recurrent cases of metastatic prostate cancer.

Phosphodiesterase-5 inhibitor use after robotic prostate cancer surgery was associated with a 57% lower risk of death.